In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.
A total of 105 isolates of Mycoplasma pneumoniae were evaluated for susceptibility to moxifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin. Moxifloxacin, a newly synthesized compound, showed the greatest activity. The MICs and MBCs at which 50 and 90% of isolates were affected were 0.15 (MIC(50) and MBC(50)) and 0.3 microg/ml (MIC(90) and MBC(90)) respectively. The results indicate that moxifloxacin might be promising an antimycoplasmal agent.
Hamamoto
K
K
Department of Bacteriology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan.
Shimizu
T
T
Fujimoto
N
N
Zhang
Y
Y
Arai
S
S
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009177:Mycoplasma pneumoniae / Q000187:drug effects*; D011804:Quinolines
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin